Geron Corporation ( and the University of Edinburgh ( announced today that they have entered into a collaboration to conduct preclinical safety and efficacy studies with three cell types derived from human embryonic stem cells (hESCs).

The cell types are hepatocytes for the treatment of liver failure and osteoblasts and chondrocytes for the treatment of musculoskeletal disorders, including osteoarthritis, bone fractures and osteoporosis. The studies, based at the University’s Centre for Regenerative Medicine, will be under the direction of Professor John Iredale, Dr. Phil Newsome, Dr. Brendon Noble and Professor Hamish Simpson.

Link []